ライフサイエンスコーパス: Chlamydia pneumoniae

1 tis mouse pneumonitis and L3 serovars and to Chlamydia pneumoniae.

2 chlamydial species Chlamydia trachomatis or Chlamydia pneumoniae.

3 bacterial DNA from several oral species and Chlamydia pneumoniae.

4 udies that have targeted patients exposed to Chlamydia pneumoniae.

5 much interest has focused on infection with Chlamydia pneumoniae.

6 zed to contain nucleic acid sequences of the Chlamydia pneumoniae 16S rRNA primers in a position flan

7 Infection with Chlamydia pneumoniae, a causative agent of acute and chr

8 Chlamydia pneumoniae, a common cause of respiratory infe

9 Infection with Chlamydia pneumoniae, a human respiratory pathogen, has

10 ystemic bacterial-entry network initiated by Chlamydia pneumoniae, a widespread opportunistic pathoge

11 We have previously demonstrated that Chlamydia pneumoniae accelerates plaque formation in apo

12 Intraperitoneal inoculation of mice with Chlamydia pneumoniae, after immunization with neural ant

13 mplement activation occurs on the surface of Chlamydia pneumoniae, an obligate intracellular Gram-neg

14 Infections with the bacterium Chlamydia pneumoniae, an RNA virus, and herpesviruses al

15 ms accounting for the potential link between Chlamydia pneumoniae and atherosclerosis are unknown.

16 o establish a causative relationship between Chlamydia pneumoniae and atherosclerosis, animal models

17 otentially strong association exists between Chlamydia pneumoniae and atherosclerosis, but the clinic

18 possible association of prior infection with Chlamydia pneumoniae and atherosclerotic risk, the contr

19 ions, have the capacity to support growth of Chlamydia pneumoniae and be activated to secrete proinfl

20 investigate a proposed relationship between Chlamydia pneumoniae and coronary heart disease, coronar

21 Moreover, both Chlamydia pneumoniae and cytomegalovirus exacerbate lesi

22 plex virus type 1 (HSV1), HSV type 2 (HSV2), Chlamydia pneumoniae and Helicobacter pylori, and C-reac

23 but new methods to detect S. pneumoniae, or Chlamydia pneumoniae and Mycoplasma pneumoniae may facil

24 Chlamydia pneumoniae and Mycoplasma pneumoniae were eval

25 wever, prospective data relating exposure to Chlamydia pneumoniae and risks of future myocardial infa

26 NA genes specific for Chlamydia trachomatis, Chlamydia pneumoniae, and Chlamydia psittaci as improved

27 tein gene (omcB) from Chlamydia trachomatis, Chlamydia pneumoniae, and Chlamydia psittaci were analyz

28 ether seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus (CMV) is an in

29 cal evidence on CHD and Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus (CMV), as well

30 to determine the presence of M. pneumoniae, Chlamydia pneumoniae, and seven respiratory viruses thro

31 present in all Chlamydia species except for Chlamydia pneumoniae, and their catalytic domains bear s

32 gionella antigens, Mycoplasma pneumoniae and Chlamydia pneumoniae antibodies from paired serums, and

33 lamydia psittaci, whereas the titers of anti-Chlamydia pneumoniae antibodies were the highest.

34 Recent observations have shown that both Chlamydia pneumoniae antigens and DNA may be found withi

35 matis (C/TW-3/OT, E/UW-5/Cx, and L2/434/Bu), Chlamydia pneumoniae (AR-39), and Chlamydia psittaci (6B

36 Helicobacter pylori and Chlamydia pneumoniae are both pathogenic to humans.

37 mitochondrial DNA and viral factors such as Chlamydia pneumoniae are reviewed.

38 Chlamydia trachomatis and Chlamydophila (Chlamydia) pneumoniae are known triggers of reactive art

39 We found that recombinant Chlamydia pneumoniae ArgR functions as an arginine-depen

40 f tumor necrosis factor alpha (TNF-alpha) in Chlamydia pneumoniae atherogenesis was evaluated in TNF-

41 med using primers for Chlamydia trachomatis, Chlamydia pneumoniae, Borrelia burgdorferi, and pan bact

42 GF2) was shown to enhance the infectivity of Chlamydia pneumoniae but not C. trachomatis in endotheli

43 fic to Chlamydiales and were confirmed to be Chlamydia pneumoniae by a C. pneumoniae-specific ompA-ba

44 t studies have suggested that infection with Chlamydia pneumoniae (C pneumoniae) may contribute to th

45 Chlamydia pneumoniae can infect arterial cells.

46 Chlamydia pneumoniae causes community-acquired pneumonia

47 the same tube) and could discriminate among Chlamydia pneumoniae, Chlamydia psittaci, and Chlamydia

48 Heat shock protein 60 derived from Chlamydia pneumoniae (cHSP60) activates Toll-like recept

49 Chlamydia pneumoniae commonly causes respiratory infecti

50 ly of polymorphic membrane proteins (Pmp) in Chlamydia pneumoniae consists of 21 members.

51 Heterologous expression of Chlamydia pneumoniae CopN in yeast and mammalian cells r

52 The Chlamydia pneumoniae CopN protein is a member of the Yop

53 nce of the association between elevated anti-Chlamydia pneumoniae (Cp) antibody titres and coronary h

54 Cytomegalovirus (CMV) and Chlamydia pneumoniae (CP) possibly contribute to atheros

55 IgA antibody to Chlamydia pneumoniae (CP)>or=1:64 was considered indicat

56 In the mouse model of Chlamydia pneumoniae (Cpn) infection, this immunity is c

57 nity to the intracellular bacterial pathogen Chlamydia pneumoniae (Cpn).

58 cells play an essential role in immunity to Chlamydia pneumoniae (Cpn).

59 It has been suggested that infection with Chlamydia pneumoniae(CPn) can trigger inflammatory mecha

60 were not serovar restricted or confounded by Chlamydia pneumoniae cross-reactivity.

61 nome of the obligate intracellular bacterium Chlamydia pneumoniae CWL029 encodes a family of 21 prote

62 [CRP]) and infection (eg, seropositivity to Chlamydia pneumoniae, cytomegalovirus [CMV], and Helicob

63 Chlamydia pneumoniae, cytomegalovirus and Helicobacter p

64 ms of human properdin bind to the surface of Chlamydia pneumoniae directly.

65 previously shown that different isolates of Chlamydia pneumoniae display heterogeneity in the in vit

66 d strain 129 mice infected intranasally with Chlamydia pneumoniae displayed a moderate-to-severe infl

67 Mouse models were used to determine whether Chlamydia pneumoniae establishes chronic infection of th

68 ata have shown that the respiratory pathogen Chlamydia pneumoniae expresses an altered gene transcrip

69 Three methods for the recovery of Chlamydia pneumoniae from spiked nasopharyngeal and bloo

70 e need to understand the transmissibility of Chlamydia pneumoniae from systemic infections in order t

71 The isolation of Chlamydia pneumoniae from the cerebrospinal fluid (CSF)

72 Chlamydia pneumoniae has been associated with atheroscle

73 Chlamydia pneumoniae has been associated with atheroscle

74 Chlamydia pneumoniae has been detected in atheroscleroti

75 Chlamydia pneumoniae has been found within atherosclerot

76 Chlamydia pneumoniae has been hypothesized to play a rol

77 Chlamydia pneumoniae has been identified in coronary ath

78 Infection with Chlamydia pneumoniae has been implicated as a potential

79 Because chronic infection with Chlamydia pneumoniae has been implicated in the pathogen

80 Chlamydia pneumoniae has been postulated to cause system

81 Chlamydia pneumoniae has been reported as a possible con

82 Chlamydia pneumoniae has been shown to accelerate athero

83 Chlamydia pneumoniae has been shown to possess at least

84 Chlamydia pneumoniae has recently been associated with a

85 One particular bacterium, Chlamydia pneumoniae, has been observed at high frequenc

86 Both cytomegalovirus (CMV) and Chlamydia pneumoniae have been associated with atheroscl

87 Chlamydia pneumoniae have been demonstrated in atheroscl

88 To date attempts to use this approach with Chlamydia pneumoniae have failed.

89 Certain pathogens, including Chlamydia pneumoniae, have evolved mechanisms to subvert

90 Many pathogens, including Chlamydophila (Chlamydia) pneumoniae, have been associated with MS.

91 us other infectious agents (cytomegalovirus, Chlamydia pneumoniae, Helicobacter pylori, and herpes si

92 obulin-G antibody titers to cytomegalovirus, Chlamydia pneumoniae, Helicobacter pylori, hepatitis A v

93 serological evidence of prior infection with Chlamydia pneumoniae, herpes simplex virus type 1 (HSV-1

94 rterectomy were examined for the presence of Chlamydia pneumoniae, human cytomegalovirus, and bacteri

95 timulated with human cytomegalovirus (HCMV), Chlamydia pneumoniae, human heat-shock protein 60 (hHSP6

96 Chlamydia pneumoniae IgG antibodies (titers >or=1:16) we

97 Chlamydia pneumoniae IgG antibody titers are not associa

98 we found no evidence of association between Chlamydia pneumoniae IgG seropositivity and risks of fut

99 relative risks of future MI associated with Chlamydia pneumoniae IgG titers >/=1:16, 1:32, 1:64, 1:1

100 Chlamydia pneumoniae illness is poorly characterized, pa

101 We investigated the presence of Chlamydia pneumoniae in 81 normal and pathological speci

102 we measured IgG antibodies directed against Chlamydia pneumoniae in blood samples collected at basel

103 The presence of Chlamydia pneumoniae in many atherosclerotic lesions rai

104 Recent evidence has implicated Chlamydia pneumoniae in the aggravation of atheroscleros

105 In literature in which detection of Chlamydia pneumoniae in the artery is described, the met

106 Our identification of Chlamydia pneumoniae in the cerebrospinal fluid (CSF) of

107 lity" criterion of a role for infection with Chlamydia pneumoniae in the pathogenesis of human athero

108 licated specific infectious agents including Chlamydia pneumoniae in the progression of atherogenesis

109 ant percentage of healthy blood donors carry Chlamydia pneumoniae in their blood.

110 succinate on the growth of three isolates of Chlamydia pneumoniae in vitro.

111 udies implicate infectious agents, including Chlamydia pneumoniae, in the pathogenesis of atheroscler

112 Here we report that Cpn0585, a Chlamydia pneumoniae inclusion membrane protein (Inc), i

113 amydia trachomatis, Chlamydia muridarum, and Chlamydia pneumoniae inclusions, whereas GFP-Rab5, GFP-R

114 t was found that the intracellular bacterium Chlamydia pneumoniae induces foam cell formation by huma

115 Chlamydia pneumoniae induces macrophage foam cell format

116 en reading frame Cpn0797 in the cytoplasm of Chlamydia pneumoniae-infected host cells.

117 progression and the influence of infection (Chlamydia pneumoniae-infected vs. uninfected control mic

118 FP) transgenic mice were used to analyze how Chlamydia pneumoniae infection affects the adherence of

119 suggest that there is an association between Chlamydia pneumoniae infection and atherogenesis.

120 evidence have implied an association between Chlamydia pneumoniae infection and atherogenesis.

121 ing evidence supports an association between Chlamydia pneumoniae infection and atherosclerosis.

122 iological evidence of an association between Chlamydia pneumoniae infection and coronary artery disea

123 Evidence for an association between Chlamydia pneumoniae infection and coronary artery disea

124 us work has suggested an association between Chlamydia pneumoniae infection and coronary atherosclero

125 To examine a possible relationship between Chlamydia pneumoniae infection and multiple sclerosis (M

126 Chlamydia pneumoniae infection can exacerbate atheroscle

127 Chlamydia pneumoniae infection has been associated with

128 Serologic diagnosis of Chlamydia pneumoniae infection has been based on the mic

129 Chronic Chlamydia pneumoniae infection has been implicated in th

130 ed an in vitro model of long-term continuous Chlamydia pneumoniae infection in HEp-2 cells.

131 Chlamydia pneumoniae infection induces inflammatory chan

132 Chlamydia pneumoniae infection is associated with athero

133 thologic, and animal model studies show that Chlamydia pneumoniae infection is associated with corona

134 o scarring of ocular or genital tissues, and Chlamydia pneumoniae infection is associated with the de

135 Chlamydia pneumoniae infection is implicated in atherosc

136 , properdin-depleted serum could not control Chlamydia pneumoniae infection of HEp-2 cells compared w

137 Experimental and clinical studies link Chlamydia pneumoniae infection to atherogenesis and athe

138 merous studies have suggested a link between Chlamydia pneumoniae infection, atherosclerosis, and cor

139 dy showed that in contrast to infection with Chlamydia pneumoniae, infection of the lung and aorta wi

140 alence of synovial Chlamydia trachomatis and Chlamydia pneumoniae infections in patients with chronic

141 Chlamydia pneumoniae is a causative agent for many respi

142 Chlamydia pneumoniae is a common cause of pulmonary infe

143 Chlamydia pneumoniae is a common cause of upper and lowe

144 Chlamydia pneumoniae is a common human respiratory patho

145 Chlamydia pneumoniae is a common respiratory pathogen as

146 Chlamydia pneumoniae is a common respiratory pathogen th

147 Chlamydia pneumoniae is a common respiratory pathogen th

148 Chlamydia pneumoniae is a common respiratory pathogen, w

149 Chlamydia pneumoniae is a human pathogen that primarily

150 Chlamydia pneumoniae is a major human pathogen that is w

151 lopmentally regulated intracellular pathogen Chlamydia pneumoniae is a natural tryptophan auxotroph.

152 Chlamydia pneumoniae is a respiratory pathogen that has

153 Chlamydia pneumoniae is an important human pathogen, but

154 Chlamydia pneumoniae is an important respiratory pathoge

155 Chlamydia pneumoniae is an intracellular bacterium respo

156 Chlamydia pneumoniae is an obligate intracellular human

157 Chlamydia pneumoniae is an obligate intracellular parasi

158 Chlamydia pneumoniae is an obligate intracellular pathog

159 Chlamydia pneumoniae is an obligate intracellular pathog

160 Chlamydia pneumoniae is an obligate intracellular prokar

161 Chlamydia pneumoniae is an omnipresent obligate intracel

162 ether past use of antibiotics active against Chlamydia pneumoniae is associated with a decrease in th

163 Chlamydia pneumoniae is associated with atherosclerosis

164 gic studies suggest that past infection with Chlamydia pneumoniae is associated with clinical and sub

165 Chlamydia pneumoniae is associated with coronary artery

166 Infection with Helicobacter pylori and Chlamydia pneumoniae is associated with coronary heart d

167 Chlamydia pneumoniae is commonly detected in atheroscler

168 Chlamydia pneumoniae is detected by macrophages and othe

169 trast, it has been reported that the MOMP of Chlamydia pneumoniae is not surface exposed and is immun

170 Chlamydia pneumoniae is one possible pathogen.

171 ntly that the bacterial respiratory pathogen Chlamydia pneumoniae is present in the cerebrospinal flu

172 and harvest of purified elementary bodies of Chlamydia pneumoniae is presented.

173 Chlamydia pneumoniae is the causative agent of respirato

174 The intracellular bacterium Chlamydophila ("Chlamydia") pneumoniae is a pathogen for several respira

175 This toxin gene, not present in Chlamydia pneumoniae, is a member of the YopT effector f

176 Replication of Chlamydia pneumoniae isolates A-03 and BAL-16 was inhibi

177 ance has not yet been described in wild type Chlamydia pneumoniae isolates, nor has selective emergen

178 the immune and disease responses to repeated Chlamydia pneumoniae lung infection by multivariate mode

179 based on the hypothesis that infection with Chlamydia pneumoniae may be causally associated with car

180 Recent reports have suggested that Chlamydia pneumoniae may play a role in the pathogenesis

181 ecognize corresponding peptides derived from Chlamydia pneumoniae MOMP, further suggesting that they

182 s been implicated in asthma inception, while Chlamydia pneumoniae, Mycoplasma pneumoniae, and latent

183 Attributes of Chlamydia pneumoniae of potential importance to a relati

184 The effect of infection with Chlamydia pneumoniae on host messenger RNA expression in

185 The hypothetical protein encoded by Chlamydia pneumoniae open reading frame cpn0308 was dete

186 nfection with very common organisms, such as Chlamydia pneumoniae or cytomegalovirus, may lead to a l

187 utions of the antibiotics, and infected with Chlamydia pneumoniae or stimulated with tumor necrosis f

188 We therefore conclude that viable Chlamydia pneumoniae organisms are frequently present in

189 t 30 publications from 1992 to 1999 describe Chlamydia pneumoniae organisms in atherosclerotic lesion

190 f the major outer membrane protein (MOMP) of Chlamydia pneumoniae, peptides representing these areas

191 The common respiratory pathogen Chlamydia pneumoniae recently has been implicated as a r

192 Exposure of human monocytes to Chlamydia pneumoniae resulted in a significant enhanceme

193 We show that AmiA from Chlamydia pneumoniae separates daughter cells in an Esch

194 We also assessed Helicobacter pylori and Chlamydia pneumoniae serology.

195 tudy was to examine the relationship between Chlamydia pneumoniae seropositivity and aortic atheroscl

196 Associations have been reported between Chlamydia pneumoniae seropositivity and both acute and c

197 quence comparison between C. trachomatis and Chlamydia pneumoniae showed less conservation between sp

198 onitis (MoPn) strain Nigg (1 069 412 nt) and Chlamydia pneumoniae strain AR39 (1 229 853 nt) were det

199 cans (GAGs) in the invasion of host cells by Chlamydia pneumoniae strains TW-183 and A-03 was investi

200 rms accelerates complement activation on the Chlamydia pneumoniae surface, as measured by C3b and C9

201 inis-like mycoplasma from a stock culture of Chlamydia pneumoniae TW-183 obtained from the American T

202 To date, use of MIF serology with Chlamydia pneumoniae (TWAR) antigen has provided the mos

203 Chlamydia pneumoniae (TWAR), a common cause of acute res

204 Chlamydia pneumoniae was cultured from atherosclerotic p

205 Chlamydia pneumoniae was the causative pathogen of this

206 required for infection by C. trachomatis and Chlamydia pneumoniae were characterized.

207 However, the regulation of infection with Chlamydia pneumoniae, which is a ubiquitous pneumonia-ca